Key result
mRNA-1273 vaccination and prior SARS-CoV-2 exposure induced higher neutralization capacity and antibody levels (p<0.05); a second dose did not increase levels in pre-exposed individuals.
Why the study?
It was unclear whether a second mRNA vaccine dose is needed to maximize effectiveness in individuals previously exposed to SARS-CoV-2 and what other factors affect responsiveness.
Does COVID-19 mRNA vaccination induce different antibody responses based on prior SARS-CoV-2 exposure, vaccine brand, and patient characteristics in healthcare workers?
Population
578 health care workers
Comparison
BNT162b2 vs mRNA-1273 vaccination across COVID-19 history, doses, comorbidities, and adverse events
Design
Cohort study
Follow-up
Up to 189 days post-vaccination
Loading...
May support single-dose strategies in previously exposed adults; leaves open optimal dosing and variant durability questions.
Cohort (n=578)
Does COVID-19 mRNA vaccination induce different antibody responses based on prior SARS-CoV-2 exposure, vaccine brand, and patient characteristics in healthcare workers?
p-value: p=<0.05
A single dose of mRNA vaccine may be sufficient for primary vaccination in previously SARS-CoV-2 exposed healthy individuals, though responses vary by vaccine brand, comorbidities, and smoking status.
A 2022 study conducted a cohort in COVID-19 (n=578). COVID-19 mRNA vaccination and prior SARS-CoV-2 exposure vs. Naive individuals and BNT162b2 vaccination was evaluated on IgA, IgG and IgM levels and neutralizing capacity against SARS-CoV-2 antigens (p=<0.05). mRNA-1273 vaccination and prior SARS-CoV-2 exposure induced higher neutralization capacity and antibody levels (p<0.05); a second dose did not increase levels in pre-exposed individuals.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: